Though the COVID-19 pandemic endures, we at Cumberland Pharmaceuticals remain hopeful as vaccination rates continue to rise. We are carefully monitoring the situation so that we can act quickly, if necessary, to keep our employees safe and our business strong. 


Last year was one of the most difficult operating environments we have ever faced, but our diversified product portfolio helped us weather the pandemic and offset its negative effects – for example, Kristalose®, Vaprisol® and Vibativ® delivered a strong performance throughout the first half of this year.


We are pleased to announce our 2020 Sustainability Report, which outlines our activities relating to environmental, social and governance (ESG) matters. Some highlights of this report include:

  • Provided nearly 2.5 million doses of our products for patients
  • Safely disposed of over 4,000 pounds of expired or damaged goods
  • No products were recalled and no clinical trials were terminated due to failure to practice good clinical standards 
  • Serialized all commercial products distributed in the U.S. to help prevent counterfeit drugs from entering the market under the Cumberland brand
  • Engaged with the community, hosted a special fundraising event to provide food & shelter for the needy
  • Invested in our employees through education, development, education and recognition initiatives 


We also had several other company developments in the second quarter, including: the appointment of John Hamm to Senior Director of Finance & Accounting and Chief Financial Officer; the release of a case study dossier outlining the success of Vibativ® product in treating COVID-19 patients with secondary bacterial infections; and the forgiveness of our $2.2 million Paycheck Protection Program loan.


We look forward to launching our FDA-approved RediTrex® product line of injectable methotrexate products nationally in late September 2021. 


Thank you to our team for their continued dedication in our mission to advance patient care through the delivery of high-quality medicines. We remain committed to supplying our products, building a differentiated product portfolio and growing our business in the second half of the year.